Clinical Trials Logo

Clinical Trial Summary

The purpose of this prospective, multi-center, randomized, triple-blind, sham-controlled study with parallel economic evaluation is to test the analgesic superiority of BurstDR-SCS compared to sham stimulation using both traditional patient-reported pain outcome measures and objective physiologic data collected from patient-worn biosensors. The endpoints associated with these objectives will be studied across a follow-up period of 6 months.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06030284
Study type Interventional
Source Abbott Medical Devices
Contact
Status Withdrawn
Phase N/A
Start date April 20, 2023
Completion date June 1, 2023

See also
  Status Clinical Trial Phase
Terminated NCT00414466 - A Safety and Effectiveness Study of Intraspinal Gabapentin (MDT2004) for the Treatment of Chronic Pain Phase 2